{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:04:11Z","timestamp":1779109451702,"version":"3.51.4"},"reference-count":108,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clindermatol.2021.12.008","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T02:16:15Z","timestamp":1640916975000},"page":"450-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Annular drug eruptions"],"prefix":"10.1016","volume":"40","author":[{"given":"Wei-Hsin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Yu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2021.12.008_bib0001","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1001\/jama.1986.03380240052027","article-title":"Drug-induced cutaneous reactions. A report from the Boston collaborative drug surveillance program on 15,438 consecutive inpatients, 1975 to 1982","volume":"256","author":"Bigby","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0002","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1398-9995.1997.tb01017.x","article-title":"Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey","volume":"52","author":"Hunziker","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0003","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0004","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/0019-5154.39732","article-title":"Adverse cutaneous drug reaction","volume":"53","author":"Nayak","year":"2008","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0007","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/ijms18061243","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system","author":"Cho","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0008","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.14841","article-title":"Re-evaluation of \u2018drug-induced\u2019 erythema multiforme in the medical literature","volume":"175","author":"Roujeau","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0009","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1081-1206(10)61804-2","article-title":"Drug allergy in a general hospital: results of a novel prospective inpatient reporting system","volume":"90","author":"Thong","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0010","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/cup.13047","article-title":"Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem","volume":"44","author":"Singh","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0011","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaad.2016.08.034","article-title":"Viral exanthems: an update on laboratory testing of the adult patient","volume":"76","author":"Korman","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0012","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0013","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0014","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.dsi.2013.09.006","article-title":"Drug reaction with eosinophilia and systemic symptoms: a drug-induced hypersensitivity syndrome with variable clinical features","volume":"31","author":"Chen","year":"2013","journal-title":"Dermatol. Sin."},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0015","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0016","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archdermatol.2010.198","article-title":"Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases","volume":"146","author":"Chen","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0017","first-page":"203","article-title":"Severe cutaneous adverse reactions to drugs (SCAR): definitions, diagnostic criteria, genetic predisposition","volume":"27","author":"Roujeau","year":"2009","journal-title":"Dermatol Sin"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0018","first-page":"693","article-title":"DRESS syndrome. Part I: clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0019","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archderm.134.9.1108","article-title":"Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome","volume":"134","author":"Suzuki","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0020","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archderm.134.9.1113","article-title":"Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6","volume":"134","author":"Tohyama","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0021","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1365-2133.2007.08167.x","article-title":"Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome","volume":"157","author":"Tohyama","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0022","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2133.2006.07332.x","article-title":"Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome","volume":"155","author":"Seishima","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0023","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0024","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.13688","article-title":"HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study","volume":"173","author":"Cheng","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0026","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0027","first-page":"709","article-title":"DRESS syndrome. Part II: management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0028","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamadermatol.2016.2220","article-title":"Cyclosporine treatment of drug-induced hypersensitivity syndrome","volume":"152","author":"Kirchhof","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0029","first-page":"41","article-title":"Cyclosporine treatment of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report and brief review of the literature","volume":"2018","author":"Kuschel","year":"2018","journal-title":"Pract Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","article-title":"Acute generalized exanthematous pustulosis (AGEP): a review and update","volume":"73","author":"Szatkowski","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0031","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/archderm.142.8.1080","article-title":"Acute generalized exanthematous pustulosis induced by clindamycin","volume":"142","author":"Kapoor","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0032","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.clinthera.2008.05.014","article-title":"Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature","volume":"30","author":"Paradisi","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0033","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2133.2005.06393.x","article-title":"Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature","volume":"152","author":"Beltraminelli","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0034","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3390\/ijms17081214","article-title":"Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy","volume":"17","author":"Feldmeyer","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0035","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/archderm.1991.01680080069004","article-title":"Acute generalized exanthematous pustulosis: analysis of 63 cases","volume":"127","author":"Roujeau","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0036","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.12502","article-title":"Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients","volume":"169","author":"Hotz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0037","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP): results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0038","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2133.2010.09967.x","article-title":"EuroSCAR and RegiSCAR study group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases","volume":"163","author":"Halevy","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0039","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2340\/00015555-0438","article-title":"Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia","volume":"88","author":"Chang","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP)\u2013a clinical reaction pattern","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0041","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jid.2018.10.023","article-title":"Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis","volume":"139","author":"Meier-Schiesser","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0042","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2230.2011.04129.x","article-title":"A diagnostic challenge: acute generalized exanthematous pustulosis or pustular psoriasis due to terbinafine","volume":"37","author":"Duckworth","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0043","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000488076","article-title":"A case of ceftriaxone-induced acute generalized exanthematous pustulosis\/generalized pustular psoriasis overlap","volume":"10","author":"Zheng","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0044","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/1346-8138.14476","article-title":"Case of generalized pustular psoriasis that might have progressed from terbinafine-induced acute generalized exanthematous pustulosis","volume":"45","author":"Yasuno","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0045","first-page":"215","article-title":"Clinicopathologic retrospective analysis of annular pustular psoriasis","volume":"27","author":"Owczarczyk-Saczonek","year":"2018","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0046","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1684\/ejd.2013.2184","article-title":"Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type)","volume":"23","author":"Du-Thanh","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0047","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0048","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/1523-1747.ep12277397","article-title":"Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme","volume":"93","author":"Brice","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0049","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/1523-1747.ep12495372","article-title":"Detection of viral DNA within skin of healed recurrent herpes simplex infection and erythema multiforme lesions","volume":"98","author":"Miura","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0050","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaad.2018.03.013","article-title":"Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: a single-center series of 33 cases compared with 100 cases induced by other causes","volume":"79","author":"Amode","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0051","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaad.2014.06.026","article-title":"Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review","volume":"72","author":"Canavan","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0052","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0053","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0190-9622(83)80003-6","article-title":"Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes","volume":"8","author":"Huff","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0054","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.16928","article-title":"A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices","volume":"179","author":"Kechichian","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0055","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/archpedi.1997.02170470048009","article-title":"Herpes simplex virus-associated erythema multiforme in prepubertal children","volume":"151","author":"Weston","year":"1997","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0056","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1346-8138.1997.tb02524.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme","volume":"24","author":"Roujeau","year":"1997","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0057","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0058","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0059","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1443-1661.2012.01248.x","article-title":"Colonic involvement in Stevens-Johnson syndrome: a rare entity","volume":"24","author":"Jha","year":"2012","journal-title":"Dig Endosc"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0060","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0061","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0062","first-page":"107","article-title":"HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome\/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies","volume":"65","author":"Li","year":"2015","journal-title":"Drug Res (Stuttg)"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18433\/J36S7D","article-title":"Association between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions: a systematic review and meta-analysis","volume":"21","author":"Tangamornsuksan","year":"2018","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0064","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0065","first-page":"6","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0066","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0067","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0068","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0069","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0070","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0071","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0190-9622(88)70236-4","article-title":"Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap","volume":"19","author":"Wojnarowska","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0072","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0738-081X(93)90161-5","article-title":"Drug-induced linear immunoglobulin A disease","volume":"11","author":"Collier","year":"1993","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0073","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/archderm.144.6.774","article-title":"A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis","volume":"144","author":"Billet","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0074","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/bjd.12488","article-title":"Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms","volume":"169","author":"Chanal","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0075","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bcp.13827","article-title":"Drug-induced linear immunoglobulin A bullous dermatosis: a French retrospective pharmacovigilance study of 69 cases","volume":"85","author":"Garel","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0076","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2340\/00015555-3154","article-title":"Drug-induced linear IgA bullous dermatosis: a case report and review of the literature","volume":"99","author":"Lammer","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0077","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1440-0960.2001.00515.x","article-title":"Drug-induced linear IgA bullous disease following antibiotics","volume":"42","author":"Wiadrowski","year":"2001","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0078","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2133.2011.10397.x","article-title":"Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart","volume":"165","author":"Marzano","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0079","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1684\/ejd.2016.2912","article-title":"Drug-induced cutaneous lupus erythematosus: 88 new cases","volume":"27","author":"Laurinaviciene","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0080","first-page":"465","article-title":"A systematic review of drug-induced subacute cutaneous lupus erythematosus","volume":"164","author":"Lowe","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0081","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D380D8301D","article-title":"Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center","volume":"12","author":"Atzori","year":"2006","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0082","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/1346-8138.12562","article-title":"Pityriasis rosea and pityriasis rosea-like eruption: can they be distinguished?","volume":"41","author":"Drago","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0083","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jdcr.2018.04.002","article-title":"Pityriasis rosea and pityriasis rosea-like eruptions: how to distinguish them?","volume":"4","author":"Drago","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0084","first-page":"166","article-title":"Pityriasis rosea-like eruption due to bismuth","volume":"77","author":"Hanjani","year":"2006","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1346-8138.2005.tb00917.x","article-title":"Pityriasis rosea-like eruption due to ergotamine: a case report","volume":"32","author":"Aydogan","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0086","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4103\/0253-7613.169574","article-title":"Terbinafine induced pityriasis rosea-like eruption","volume":"47","author":"George","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0087","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000018439","article-title":"Pityriasis-rosea-like eruption due to benfluorex","volume":"201","author":"Loche","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0088","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/00044011-200424080-00009","article-title":"Pityriasis rosea-like eruption due to lithium","volume":"24","author":"Senol","year":"2004","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0089","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/LGT.0b013e31825d7c5f","article-title":"Pityriasis rosea-like drug eruption due to nortriptyline in a patient with vulvodynia","volume":"17","author":"Bangash","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0090","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-2133.1996.tb03863.x","article-title":"Pityriasis rosea-like eruption in a patient receiving omeprazole","volume":"135","author":"Buckley","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0091","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/15569527.2017.1312430","article-title":"Pityriasis rosea-like eruption induced by isotretinoin","volume":"37","author":"G\u00fcrel","year":"2018","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0092","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archderm.1977.01640100135034","article-title":"Pityriasis rosea-like drug eruption secondary to metronidazole","volume":"113","author":"Maize","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0093","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.det.2015.03.015","article-title":"Granulomatous drug eruptions","volume":"33","author":"Dodiuk-Gad","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0094","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0560.1998.tb01693.x","article-title":"The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity","volume":"25","author":"Magro","year":"1998","journal-title":"J Cutan Pathol"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2021.12.008_bib0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1600-0560.2010.01518.x","article-title":"Drug-associated reversible granulomatous T cell dyscrasia: a distinct subset of the interstitial granulomatous drug reaction","author":"Magro","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0096","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.det.2015.03.005","article-title":"Reactive granulomatous dermatitis: a review of palisaded neutrophilic and granulomatous dermatitis, interstitial granulomatous dermatitis, interstitial granulomatous drug reaction, and a proposed reclassification","volume":"33","author":"Rosenbach","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0097","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jaad.2004.11.028","article-title":"Interstitial granulomatous drug reaction caused by Chinese herbal medication","volume":"52","author":"Lee","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0098","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1684\/ejd.2012.1700","article-title":"Interstitial granulomatous drug reaction to a Chinese herb extract","volume":"22","author":"Du","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0099","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1365-2133.2004.05916.x","article-title":"A case of interstitial granulomatous drug reaction due to sennoside","volume":"150","author":"Fujita","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1468-3083.2009.03428.x","article-title":"Interstitial granulomatous dermatitis with arthritis associated with trastuzumab","volume":"24","author":"Mart\u00edn","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0101","first-page":"490","article-title":"Interstitial granulomatous drug reaction due to thalidomide [published correction appears in J Eur Acad Dermatol Venereol. 2009;23:1226]","volume":"23","author":"Yazgano\u011flu","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0102","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/DAD.0b013e3181c0e14d","article-title":"Allopurinol-induced DRESS syndrome with a histologic pattern consistent with interstitial granulomatous drug reaction","volume":"36","author":"Kim","year":"2014","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0103","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000069965","article-title":"Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy","volume":"206","author":"Devos","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0104","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/ard.2007.075663","article-title":"Granuloma annulare induced by anti-tumour necrosis factor therapy","volume":"67","author":"Voulgari","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ijd.12189","article-title":"Granuloma annulare as a possible new adverse effect of topiramate","volume":"53","author":"Cassone","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0106","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00296-018-4212-0","article-title":"Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review","volume":"39","author":"Pelechas","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0107","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/15569527.2016.1269336","article-title":"Disseminated eruptive granuloma annulare induced by levetiracetam","volume":"36","author":"Sereflican","year":"2017","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.clindermatol.2021.12.008_bib0108","first-page":"305","article-title":"Vemurafenib-induced granuloma annulare","volume":"14","author":"Lee","year":"2016","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X21002662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X21002662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:19:27Z","timestamp":1760033967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X21002662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":108,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0738081X21002662"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2021.12.008","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Annular drug eruptions","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2021.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}